Extended use of brentuximab vedotin before autologous stem-cell transplantation would benefit refractory systemic anaplastic large-cell lymphoma

The optimal number of brentuximab vedotin cycles in the treatment of systemic anaplastic large-cell lymphoma (sALCL) prior to autologous stem-cell transplantation (ASCT) is unknown. This case illustrates the possible benefit of prolonged brentuximab vedotin before ASCT in sALCL and may help clinical decision-making, especially in chemorefractory disease.